DocumentRX-7289
Issued
Read3 min

FDA approves GSK’s Nelkarmi for pretreated ALK-positive lung cancer

GSK’s Nelkarmi earned accelerated FDA approval for previously treated ALK-positive NSCLC, with ALKOVE-1 response rates of 49% and 32% after prior therapy.

TAG C-6506 · 542 words on the filing

FDA Approves GSK Treatment for ALK-Positive NSCLC - Contract Pharma
FDA Approves GSK Treatment for ALK-Positive NSCLC - Contract Pharmastevepb / pixabay

Summary of findings

  • Nov. 18, 2026: FDA granted accelerated approval for GSK’s Nelkarmi in previously treated ALK-positive NSCLC.
  • The approval came nine days before the FDA’s Nov. 27 target decision date.
  • ALKOVE-1 overall response rates were 49% after alectinib alone and 32% after two or more ALK TKIs plus chemotherapy.
  • In both groups, response duration exceeded six months in at least 69% of responders and reached 12 months in 51%.
  • GSK acquired Nuvalent in July 2026; the ongoing Phase III ALKAZAR trial covers TKI-naïve ALK-positive NSCLC and other solid tumors.

By Marcus Bennett

GSK’s Nelkarmi won U.S. accelerated approval for previously treated ALK-positive non-small cell lung cancer on Nov. 18, 2026. The decision landed nine days ahead of the FDA’s Nov. 27 target decision date and followed prior Breakthrough Therapy and Orphan Drug approvals for the product.

Nelkarmi is the brand name for neladalkib, which became a GSK property through the company’s July 2026 acquisition of Nuvalent. GSK Chief Scientific Officer Tony Wood said the approval made Nelkarmi GSK’s second new medicine in lung cancer this year.

Who qualifies for the accelerated approval?

The new indication covers adults with unresectable locally advanced or metastatic ALK-positive NSCLC. It applies after prior therapy and separates patients into two treatment histories:

  • One prior ALK tyrosine kinase inhibitor, specifically alectinib.
  • At least two prior ALK TKIs and platinum-based chemotherapy.

The split carries through to the supporting data. ALKOVE-1 reported separate response rates for the alectinib-only group and the multiple-TKI plus chemotherapy group, matching the two prior-treatment categories in the FDA approval.

Those cohorts define the current indication: one heavily pretreated NSCLC population and one treated previously with a single ALK inhibitor. The approval does not extend to TKI-naïve patients; GSK is studying that population in ALKAZAR.

What did ALKOVE-1 show?

FDA approval followed results from the Phase I/II ALKOVE-1 trial. Among patients treated with alectinib as their only prior ALK TKI, the overall response rate was 49%. Among patients previously treated with two or more prior ALK TKIs and chemotherapy, the overall response rate was 32%.

Both cohorts supplied durability data. Duration of response exceeded six months in at least 69% of responders and lasted 12 months in 51%. The figures apply across both prior-treatment groups, rather than to one cohort alone.

The 49% and 32% figures are overall response rates within their respective cohorts. The 69% and 51% durability figures apply to responders, not every patient in either group. Across both cohorts, the reported duration-of-response thresholds were six months and 12 months.

What design did GSK emphasize?

Wood said: “Nelkarmi is our second new medicine approved in lung cancer this year. It was designed to help address key challenges of ALK-positive non-small cell lung cancer. [This includes] broad coverage of ALK resistance mutations, ability to cross the blood-brain barrier, and high target selectivity.”

“ALK-positive patients are often younger and can remain on treatment for years, making effective, tolerable new treatment options especially important,” Wood said. “We are pleased to bring this innovation to patients in the U.S.”

What does ALKAZAR add?

GSK is also evaluating Nelkarmi in the ongoing Phase III ALKAZAR study. ALKAZAR examines TKI-naïve ALK-positive NSCLC and other solid tumors. The current approval rests on ALKOVE-1 in previously treated disease, while ALKAZAR extends the clinical program to a TKI-naïve ALK-positive NSCLC population and additional solid tumors.

For now, the U.S. indication remains confined to those two previously treated groups, while the Phase III program tests Nelkarmi in TKI-naïve NSCLC and other solid tumors. GSK’s July 2026 acquisition of Nuvalent brought neladalkib into the portfolio before the Nov. 18 accelerated approval.

via FDA industry wire (Google News) (Source)

Share this article:

More from Marcus Bennett

Marcus Bennett

Show full bio

News editor covering regulation, policy and their impact on global pharmaceutical industry at PharmInsider.

6 articles

Linked filings

  1. V-1848
  2. C-9698
  3. C-7994
  4. K-5457
  5. P-9899

« Previous filing